

Remarks

Claims 1-10, 15, 17, and 27 are pending. Applicants have cancelled claim 16, writing its subject matter into claim 15.

Specification

An Abstract is provided herewith, on a separate sheet as required.

Response to Amendment

The Examiner points out that the provisional ODP rejections over U.S. Patent Application Serial Nos. 10/543,585; 10/552,456; 10/544,520; and 10/502,573 are maintained. Applicants submit herewith Terminal Disclaimers for each of the cited co-pending and commonly owned applications. This, along with amendment to address section 112 rejections (discussed below), is believed to remove the only remaining obstacle to allowability of the instant claims.

Rejection Under 35 U.S.C. § 112, First Paragraph

The Examiner has rejected claim 15 as non-enabled for the treatment of any diseases or disorders of the respiratory, urinary and gastrointestinal systems. Claim 15 has been amended to include the subject matter of claim 16, which is hereby cancelled. This is believed to address the rejection.

CONCLUSION


Applicants respectfully request a Notice of Allowance at this time.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

By:


George E. Heibel, PhD
Reg. No. 42,648

Date: July 28, 2008

Correspondence Address:
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5334
Facsimile: (609) 514-9779